Vimarsana
Biggest News Aggregation in the World

Page 19 - Breakthrough Therapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Breakthrough Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Breakthrough Therapy Today - Breaking & Trending Today

NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine) -March 11, 2024 at 08:31 am EDT - Vimarsana News

NRx Pharmaceuticals (NASDAQ:NRXP) Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine) -March 11, 2024 at 08:31 am EDT

Company to receive first allocation of ketamine for sale by month endPartners preparing to ship IV Ketamine to full range of customers via 503a and 503b pharmaciesNRx Pharmaceuticals and HOPE...

Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum's LIVMARLI -February 29, 2024 at 08:35 am EST - Vimarsana News

Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum's LIVMARLI -February 29, 2024 at 08:35 am EST

- Results demonstrate 70% risk reduction for long-term clinical outcomes in patients with Alagille syndrome treated with LIVMARLI - Data are the first to demonstrate a six-year transplant-free...

Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum's LIVMARLI - Vimarsana News

Hepatology Publishes Six-Year Data Demonstrating Improved Clinical Outcomes in Patients with Alagille Syndrome Treated with Mirum's LIVMARLI

Mirum Pharmaceuticals, Inc. today announced that Hepatology published an analysis demonstrating a statistically significant improvement in six-year event-free and transplant-free survival in patients with Alagille syndrome (ALGS) treated with...

Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment - Compass Pathways (NASDAQ:CMPS) - Vimarsana News

Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment - Compass Pathways (NASDAQ:CMPS)

Tonix Pharmaceuticals Announces Presentation at The 6th International Congress on Controversies in Fibromyalgia - Vimarsana News

Tonix Pharmaceuticals Announces Presentation at The 6th International Congress on Controversies in Fibromyalgia

CHATHAM, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical ...